News Releases
Aug 30, 2019
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Additional Formats
Aug 07, 2019
Sangamo Therapeutics Reports Second Quarter 2019 Financial Results
Additional Formats
Aug 06, 2019
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Additional Formats
Jul 31, 2019
Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel
Additional Formats
Jul 31, 2019
Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast
Additional Formats
Jul 29, 2019
Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases
Additional Formats
Jul 05, 2019
Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels
Additional Formats
Jul 01, 2019
Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger Proteins in Preclinical Models of Huntington’s Disease
Additional Formats
Jun 21, 2019
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019
Additional Formats
May 15, 2019
Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences
Additional Formats
Displaying 11 - 20 of 44